1 Main Capital
Our archive holds 7 letters from 1 Main Capital, behind 8 investment theses and positions in 2 companies. Every quote below is copied verbatim from the letter it came from.
What they bought and sold · 1 move
- New positionHilton Grand VacationsJune 2026
“Earlier this year, the Fund initiated a position in Hilton Grand Vacations (HGV), a global timeshare company that develops, markets, sells, manages, and operates timeshare resorts primarily under the Hilton Grand Vacations brand.”
Read the letter
Companies held · 2
Every company 1 Main Capital has disclosed a position in across our archive, with the letter that last mentioned it.
- DiaMedica TherapeuticsJun 2026
- Hilton Grand VacationsJun 2026
Theses · 8
- June 2026
Hilton Grand Vacations is a branded timeshare operator with recurring, capital-light cash flows, attractive financing economics, and a depressed valuation that could rerate as FCF compounds.
Read the full thesis - June 2026
DiaMedica Therapeutics is a clinical-stage biotech pursuing DM199 for stroke and preeclampsia, supported by prior KLK1 human data, a science-driven subgroup signal, and a long runway to key catalysts.
Read the full thesis - March 2026
International Workplace Group is a flexible workspace leader expected to benefit from AI-driven demand and an asset-light model, with mid-term growth, EBITDA targets, and a compelling long-term valuation.
Read the full thesis - March 2026
KKR & Co is a diversified, scaled alternative asset manager with strong fee economics, long AUM runway, limited exposure to feared risks, and attractive valuation supported by insider buying.
Read the full thesis - December 2025
Limbach Holdings is a leading building systems solutions firm benefiting from a shift to higher-margin owner-direct work, strong cash generation, accretive acquisitions, and potential for ~20% FCF per share CAGR.
Read the full thesis - September 2025
Radiant Logistics is an undervalued non-asset based 3PL company with a strong acquisition strategy and a robust growth potential, currently trading at a significant discount to larger peers.
Read the full thesis - June 2025
MasterCraft Boat is a well-established manufacturer poised for growth as the market normalizes, offering attractive long-term value despite current volatility.
Read the full thesis - March 2025
Arvinas (ARVN) is a clinical-stage biotech company with significant cash reserves and collaboration agreements, but its market value has plummeted over 90% due to disappointing trial results.
Read the full thesis
Letter archive · 7
Funds · 3
- 1 Main Capital5
- 1 Main Capital Partners, L.P.1
- Main Capital1
Get 1 Main Capital’s next letter the day it lands
We track 1 Main Capital alongside hundreds of other managers, read every letter, and pull out what they bought and sold. Warren AI reads the whole archive for you.
View plans→